[go: up one dir, main page]

CY1111191T1 - Θεραπευτικος παραγοντας για την διαταραχη του κερατο-επιπεφυκοτα - Google Patents

Θεραπευτικος παραγοντας για την διαταραχη του κερατο-επιπεφυκοτα

Info

Publication number
CY1111191T1
CY1111191T1 CY20111100206T CY111100206T CY1111191T1 CY 1111191 T1 CY1111191 T1 CY 1111191T1 CY 20111100206 T CY20111100206 T CY 20111100206T CY 111100206 T CY111100206 T CY 111100206T CY 1111191 T1 CY1111191 T1 CY 1111191T1
Authority
CY
Cyprus
Prior art keywords
corneal
keratitis
ylmethoxy
benzimidazol
dione
Prior art date
Application number
CY20111100206T
Other languages
English (en)
Inventor
M Nakamura
S Hirai
Original Assignee
Santen Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd filed Critical Santen Pharmaceutical Co., Ltd
Publication of CY1111191T1 publication Critical patent/CY1111191T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Στόχος της παρούσας εφεύρεσης είναι η έρευνα για μια νέα φαρμακευτική χρήση της 5-[4-(6-μεθοξυ-1-μεθυλο-1Η-βενζιμιδαζολ-2-υλομεθοξυ)βενζυλο]θειαζολιδινο-2,4-διόνης η οποία είναι μια συμπυκνωμένη ετεροκυκλική ένωση, ή ενός άλατός της. Η 5-[4-(6-μεθοξυ-1-μεθυλο-1Η-βενζιμιδαζολ-2-υλομεθοξυ)βενζυλο]θειαζολιδινο-2,4-διόνη ή ένα άλας της μπορεί να ασκεί μια εξαιρετική επίδραση στο να προάγει την ίαση σε ένα μοντέλο ξηρού οφθαλμού, και είναι χρήσιμη ως θεραπευτικός παράγοντας για τις διαταραχές του κερατοεπιπεφυκότα όπως είναι οι ξηροί οφθαλμοί, το κερατοειδικό έλκος, η κερατίτιδα, η επιπεφυκίτιδα, η επιπολής διάστικτη κερατοπάθεια, τα κερατοειδικά επιθηλιακά ελαττώματα, τα επιθηλιακά ελαττώματα του επιπεφυκότα, η ξηρά κερατοεπιπεφυκίτιδα, η άνω στεφανιαία κερατοεπιπεφυκίτιδα και η νηματώδης κερατίτιδα.
CY20111100206T 2003-10-24 2011-02-18 Θεραπευτικος παραγοντας για την διαταραχη του κερατο-επιπεφυκοτα CY1111191T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003364864 2003-10-24
EP04793171A EP1679074B1 (en) 2003-10-24 2004-10-22 Therapeutic agent for keratoconjunctive disorder

Publications (1)

Publication Number Publication Date
CY1111191T1 true CY1111191T1 (el) 2015-06-11

Family

ID=34510137

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100206T CY1111191T1 (el) 2003-10-24 2011-02-18 Θεραπευτικος παραγοντας για την διαταραχη του κερατο-επιπεφυκοτα

Country Status (16)

Country Link
US (1) US7358255B2 (el)
EP (1) EP1679074B1 (el)
JP (1) JP4217832B2 (el)
KR (1) KR101154175B1 (el)
CN (1) CN1870997B (el)
AT (1) ATE490771T1 (el)
CA (1) CA2543452C (el)
CY (1) CY1111191T1 (el)
DE (1) DE602004030470D1 (el)
DK (1) DK1679074T3 (el)
ES (1) ES2357801T3 (el)
PL (1) PL1679074T3 (el)
PT (1) PT1679074E (el)
SI (1) SI1679074T1 (el)
TW (1) TWI343256B (el)
WO (1) WO2005039574A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1681054A1 (en) * 2003-10-29 2006-07-19 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctiva disorder
WO2006064825A1 (ja) * 2004-12-14 2006-06-22 Santen Pharmaceutical Co., Ltd. ドライアイ治療剤
CA2630816C (en) * 2005-11-28 2014-08-12 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
SG10201506912RA (en) 2005-12-13 2015-10-29 Incyte Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR101508020B1 (ko) 2007-05-21 2015-04-06 센주 세이야꾸 가부시키가이샤 Ｐｐａｒδ 아고니스트 함유 의약
SI2740731T1 (sl) 2007-06-13 2016-07-29 Incyte Holdings Coroporation Kristalinične soli inhibitorja za janus kinazo (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopen tilpropannitrila
KR20100137417A (ko) 2008-02-25 2010-12-30 산텐 세이야꾸 가부시키가이샤 각막 상피 배리어 기능 항진제
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
MY161416A (en) * 2009-05-22 2017-04-14 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
KR101771401B1 (ko) 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 야누스 키나제 억제제로서 피라졸­４­일­피롤로［２,３­ｄ］피리미딘 및 피롤­３­일­피롤로［２,３­ｄ］피리미딘의 Ｎ­(헤테로)아릴­피롤리딘 유도체
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI850648B (zh) 2010-03-10 2024-08-01 美商英塞特控股公司 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
MY178634A (en) 2010-05-21 2020-10-19 Incyte Corp Topical formulation for a jak inhibitor
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
PH12013501001A1 (en) 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TWI577676B (zh) 2011-06-20 2017-04-11 英塞特控股公司 作為ｊａｋ抑制劑之吖丁啶基苯基、吡啶基或吡基羧醯胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
HUE055894T2 (hu) 2012-11-15 2021-12-28 Incyte Holdings Corp A ruxolitinib nyújtott felszabadulású dózisformái
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
CR20190343A (es) 2013-08-07 2019-10-02 Incyte Corp FORMAS DE DOSIFICACIÓN DE LIBERACIÓN PROLONGADA PARA UN INHIBIDOR DE JAK 1 (Divisional de Exp: 2016-0102)
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
HRP20220510T1 (hr) 2018-01-30 2022-05-27 Incyte Corporation Postupci za pripravu (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona)
FI3773593T3 (fi) 2018-03-30 2024-06-18 Incyte Corp Hidradenitis suppurativan hoito jak-estäjiä käyttäen
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3769066D1 (de) 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
JP3072227B2 (ja) * 1994-08-01 2000-07-31 株式会社クボタ 田植機の粉粒体供給装置
JP3603129B2 (ja) 1994-12-28 2004-12-22 株式会社三和化学研究所 糖尿病性角膜症の治療剤
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
US5885997A (en) 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
CN1190434C (zh) 1996-12-31 2005-02-23 雷迪实验室有限公司 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
JPH11130675A (ja) * 1997-08-29 1999-05-18 Santen Pharmaceut Co Ltd クロマン誘導体含有点眼液
EP0909558A3 (en) * 1997-08-29 1999-10-27 Santen Pharmaceutical Co., Ltd. Chroman derivative containing ophthalmic solution
JP2001039976A (ja) 1999-05-24 2001-02-13 Sankyo Co Ltd 縮合複素環化合物の塩酸塩
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
JP2002220336A (ja) 2000-11-22 2002-08-09 Sankyo Co Ltd 縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬
JP4090013B2 (ja) 2000-12-26 2008-05-28 第一三共株式会社 利尿剤及びインスリン抵抗性改善剤を含有する医薬組成物
EP1681054A1 (en) 2003-10-29 2006-07-19 Santen Pharmaceutical Co., Ltd. Therapeutic agent for keratoconjunctiva disorder

Also Published As

Publication number Publication date
JP4217832B2 (ja) 2009-02-04
US20070060628A1 (en) 2007-03-15
CA2543452A1 (en) 2005-05-06
EP1679074A1 (en) 2006-07-12
CA2543452C (en) 2012-03-13
DK1679074T3 (da) 2011-03-21
KR20060100440A (ko) 2006-09-20
DE602004030470D1 (de) 2011-01-20
CN1870997A (zh) 2006-11-29
EP1679074A4 (en) 2009-03-25
PL1679074T3 (pl) 2011-05-31
US7358255B2 (en) 2008-04-15
KR101154175B1 (ko) 2012-06-14
JP2005145961A (ja) 2005-06-09
TWI343256B (en) 2011-06-11
EP1679074B1 (en) 2010-12-08
ATE490771T1 (de) 2010-12-15
WO2005039574A8 (ja) 2005-06-23
SI1679074T1 (sl) 2011-04-29
ES2357801T3 (es) 2011-04-29
WO2005039574A1 (ja) 2005-05-06
PT1679074E (pt) 2011-03-03
CN1870997B (zh) 2011-05-04
TW200518750A (en) 2005-06-16

Similar Documents

Publication Publication Date Title
CY1111191T1 (el) Θεραπευτικος παραγοντας για την διαταραχη του κερατο-επιπεφυκοτα
UY26480A1 (es) Inhibidores de n - (5 - ( 5 - alquil - 2 - oxazolil) metil ) tio) - 2 - tiazolil) - carboxamida de cinasas dependientes de ciclina
NO2010020I1 (no) 5-{{4-[(2,3-dimetyl-2H-indazot-6-yl)(metyl)amino]pyrimidin-2-yl}amino)-2-metylbenzensulfonamid Pazopanib.
NO20062303L (no) Pyrazinderivater og farmasoytisk anvendelse derav
EA200401114A3 (ru) Замещённые гидроксиэтиламины
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
DK1358184T3 (da) N-(3,3-dimethylindolin-6-yl){2-[4-pyridylmethyl)amino](3-pyridyl)}carboxamid samt farmacaceutiske sammensætninger deraf
PE20040581A1 (es) Inhibidores heterociclicos de cinasas
DK1798223T3 (da) Arylsulfonamider
NO20073465L (no) Benzotiazol-derivater
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
UY26481A1 (es) Inhibidores de n - (5 - ( ( (5 - alquil - 2 - oxazolil) metil) tio) - 2 - tiazolil) - carboxamida de cinasas dependientes de ciclina.
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
PE20090837A1 (es) Nuevos compuestos quimicos
ATE384058T1 (de) Thiazolderivate
CY1106526T1 (el) Παραγωγα ν-θειαζολ-2-υλο-βενζαμιδης
EA200700112A1 (ru) Производные сульфонамидов, их получение и применение в терапии
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
NO20060702L (no) Aminokinolinderivater og deres anvendelse som adenosin A3 ligander
NO20001483L (no) Nye NPY-agonister
EA200700756A1 (ru) Пиримидоны